Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107913 | 1.00 | TRPV1 (0.39) | TRPV1MCHR1CYP3A4CYP3A5HTR6 | |
| SCHEMBL3099643 | 0.90 | TRPV1 (0.38) | TRPV1MCHR1CYP3A4CYP3A5HTR6 | |
| SCHEMBL3099638 | 0.90 | TRPV1 (0.38) | TRPV1MCHR1CYP3A4CYP3A5HTR6 | |
| SCHEMBL1124462 | 0.79 | TRPV1 (0.50) | TRPV1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL1124460 | 0.79 | TRPV1 (0.50) | TRPV1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL11997379 | 0.75 | HPGD (0.41) | TRPV1KDM4ENPC1HPGDRAB9A | |
| SCHEMBL27766798 | 0.70 | TRPV1 (0.45) | TRPV1KDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL2401676 | 0.69 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL2401668 | 0.69 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL13096378 | 0.68 | MAPT (0.41) | KDM4ENPC1ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318768-B2 | Bronchodilating alpha, beta-unsaturated isoquinoline amides | RESPIRATORIUS AB (SE) | 2012-11-27 | — | — | US | disclosed |
| EP-2181095-B1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2012-08-22 | — | — | EP | disclosed |
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | ARCEDE PHARMA AB (SE) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | PTGIS, ADRB2, ADRB1 | TRPV1 537/4885MCHR1 1958/4885CYP3A4 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.